 The FDA has cleared Poseida Therapeutics Inc NASDAQ: PSTX Investigational New Drug IND application for P-BCMA-ALLO1, a fully allogeneic CAR-T product candidate for relapsedrefractory multiple myeloma. The Phase 1 study will assess safety, tolerability, and response. 